Correspondence on "Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: results from the COVID-19 Global Rheumatology Alliance physician registry" by Sparks <i>et al</i>.

Gremese, Elisa; Ferraccioli, Gianfranco

Correspondence on "Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: results from the COVID-19 Global Rheumatology Alliance physician registry" by Sparks et al.

Gremese, Elisa; Ferraccioli, Gianfranco.

Gremese E; Division of Rheumatology, Università Cattolica del Sacro Cuore Facoltà di Medicina e Chirurgia, Roma, Lazio, Italy elisa.gremese@unicatt.it.
Ferraccioli G; Institute of Rheumatology, Università Cattolica del Sacro Cuore Facoltà di Medicina e Chirurgia, Roma, Lazio, Italy.

Ann Rheum Dis ; 2021 Aug 23.

Article in English | MEDLINE | ID: covidwho-20236249

Keywords

Covid-19; abatacept; glucocorticoids; therapeutics; tumor necrosis factor inhibitors

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Type of study: Prognostic study Language: English Year: 2021 Document Type: Article Affiliation country: Annrheumdis-2021-220932

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google